Physiologic and pathophysiologic effects of endothelin: Implications in cardiopulmonary disease

Journal of the American Veterinary Medical Association

Volumn 212, Issue 2, 1998, Pages 265-270

  Turk, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3;

ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOMYOPATHY; CARDIOVASCULAR AUTOREGULATION; HEART FAILURE; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; VASOMOTOR REFLEX;

ANIMAL DISEASES; ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELINS; LUNG DISEASES; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 0031915096     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Battistini B, D'Orleans-Juste P, Sirois P. Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600-628.
3. Sakurai T, Goto K. Endothelins, vascular actions and clinical implications. Drugs 1993;46:795-802.
4. Levin ER. Endothelins. N Engl J Med 1995;333:356-363.
5. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
6. Battistini B, Forget MA, Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Shock 1996;5:167-183.
7. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiologic significance of endothelin. Jpn J Pharmacol 1996;72:261-290.
8. Hickey KA, Rubanyi GM, Paul RJ, et al. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248:C550-C556.
9. Shannon TR, Hale CC. Identification of a 65 kDA endothelin receptor in bovine cardiac sarcolemmal vesicles. Eur J Pharmacol 1994;267:233-238.
10. Arai K, Ashikawa N, Nakakita Y, et al. Aspergillomarasmine A and B, potent microbial inhibitors of endothelin-converting enzyme. Biosci Biotech Biochem 1993;57:1944-1945.
11. Coceani F, Armstrong C, Kelsey L. Endothelin is a potent constrictor of the lamb ductus arteriosus. Can J Physiol Pharmacol 1989;67:902-904.
12. 450, endothelin and nitric oxide. Biochem Pharmacol 1994;48:1315-1318.
13. Stamler JS, Loh E, Roddy M, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035-2040.
14. Haynes WG, Ferr CJ, O'Kane KPJ, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93:1860-1870.
15. Adams HR. Physiologic, pathophysiologic, and therapeutic implications for endogenous nitric oxide. J Am Vet Med Assoc 1996;209:1297-1302.
16. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci U S A 1989;86:3915-3918.
17. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
18. Flowers MA, Wang Y, Stewart RJ, et al. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995;269:H1988-H1997.
19. Barker JE, Bakhle YS, Anderson J, et al. Reciprocal inhibition of nitric oxide and prostacyclin synthesis in human saphenous vein. Br J Pharmacol 1996;118:643-648.
20. 2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994;269:11938-11944.
21. Vesely DL, Chiou S, Douglass MA, et al. Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. Metabolism 1996;45:315-319.
22. Mortensen LH, Pawloski CM, Kanagy NL, et al. Chronic hypertension produced by infusion of ET-1 in rats. Hypertension 1990;15:729-733.
23. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol 1995;73:390-398.
24. Verma S, Bhanot S, McNeill LH. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995;269:H2017-H2021.
25. Robinson WF, Maxie MG. The cardiovascular system. Systemic hypertension. In: Jubb KVF, Kennedy PC, Palmer N, eds. Pathology of domestic animals. 4th ed. San Diego: Academic Press, 1993;58-59.
26. Goetz KL, Wang BC, Madwels JB, et al. Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol 1988;255:R1064-R1068.
27. B receptor antagonists. Br J Pharmacol 1997;120:516-522.
28. Garner HE, Coffman JR, Hahn AW, et al. Equine laminitis and associated hypertension: a review. J Am Vet Med Assoc 1975;166:56-57.
29. Hinckley KA, Fearn S, Howard BR, et al. Nitric oxide donors as treatment for grass induced acute laminitis in ponies. Equine Vet J 1996;28:17-28.
30. Hasegawa K, Fujiwara H, Koshiji M, et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996;27:259-264.
31. Jones LG, Gause KC, Meier KE. Effects of endothelin on mitogen-activated protein kinase activity and protein synthesis in isolated adult feline cardiac myocytes. Life Sci 1996;58:617-630.
32. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circ Res 1991;69:209-215.
33. Ho H, Adachi S, Tamamori M, et al. Mild hypoxia induces hypertrophy of cultured rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996;28:1271-1277.
34. Arai M, Yoguchi A, Iso T, et al. Endothelin-1 and its bindings sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995;268:H2084-H2091.
35. a receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994;89:2198-2203.
36. Keene BW, Bonagura JD. Therapy of heart failure. In: Bonagura JD, ed. Current veterinary therapy. XII. Philadelphia: WB Saunders Co, 1995;780-786.
37. Sakai S, Miyuchi T, Sakurai T, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-355.
38. Shimoyama H, Sabbah HN, Borzak S, et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996;94:779-784.
39. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 1992;20(Suppl):S48-S54.
40. Weber KT, Janicki JS, Pick R. Disruption of collagen tethers: anatomic basis of muscle fiber slippage in the myocardium. In: Jacob R, Seipel L, Zucker I, eds. Cardiac dilatation. New York: Gustav Fischer Verlag, 1990;18-35.
41. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-1065.
42. Guarda E, Katwa LC, Myers PR, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:2130-2134.
43. McClellan G, Weisberg A, Rose D, et al. Endothelial cell storage and release of endothelin as a cardioregulatory mechanism. Circ Res 1994;75:85-96.
44. Li K, Rouleau JL. Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog. Cardiovasc Drugs Ther 1996;10:107-112.
45. Ono K, Tsujimoto G, Sakamoto A, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994;370:301-304.
46. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-242.
47. Ando T, Ogawa K, Yamaki K, et al. Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. Chest 1996;110:462-468.
48. Mattoli S, Soloperto M, Marini M, et al. Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction. J Allerg Clin Immunol 1991;88:376-384.
49. White SR, Hathaway DP, Umans JG, et al. Epithelial modulation of airway smooth muscle response to endothelin-1. Am Rev Respir Dis 1991;144:373-378.
50. McKay KO, Armour CL, Black JL. Endothelin receptors and activity differ in human, dog, and rabbit lung. Am J Physiol 1996;270:L37-L43.
51. b receptor subtypes for antagonism of endothelin-1-induced contraction of human bronchi. Br J Pharmacol 1996;117:996-999.
52. Lüscher TF. Endothelin: systemic arterial and pulmonary effects of a new peptide with potent biologic properties. Am Rev Respir Dis 1992;146:S56-S60.
53. Heath D, Smith P, Gosney J, et al. The pathology of the early and late stages of primary-pulmonary hypertension. Br Heart J 1987;58:204-213.
54. Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Caidiovasc Surg 1995;110:271-273.
55. Sakai S, Miyuchi T, Sakurai T, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol 1996;28:1580-1588.
56. Giaid A, Yanasigawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
57. Giaid A, Michel RP, Stewart DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-1554.
58. Goerre S, Wenk M, Bartsch P, et al. Endothelin-1 in pulmonary hypertension associated with high altitude exposure. Circulation 1996;90:359-364.
59. Golden CL, Kohleer JP, Nick HS, et al. Effects of vasoactive and inflammatory mediators on endothelin-1 expression in pulmonary endothelial cells. Am J Respir Cell Mol Biol 1995;12:503-512.
60. Li H, Elton S, Chen YF, et al. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994;266:L553-L560.
61. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-2131.
62. Wang Y, Coe Y, Toyoda O, et al. Involvement of endothelin-1 in hypoxicpulmonary vasoconstriction in the lamb. J Physiol 1995;482:421-434.
63. Wong J, Vanderford PA, Winters JW, et al. Endothelin-1 does not mediate acute hypoxic pulmonary vasoconstriction in the intact newborn lamb. J Cardiovasc Pharmacol 1993;22:S262-S266.
64. Douglas SA, Vickery-Clark LM, Ohlstein EH. Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated p blood vessels: effect of BQ-123. Br J Pharmacol 1993;108:418-421.
65. Deleuze PH, Adnot S, Shiiya N, et al. Endothelin dilates bovine pulmonary circulation and reverses hypoxic pulmonary vasoconstriction. J Cardiovasc Pharmacol 1992;19:354-360.